Top Atherosclerosis Companies in Thailand | Key Players 2026

Top Atherosclerosis Companies in Thailand

The following is a data-backed list of the leading Thailand Atherosclerosis companies, compiled through 6Wresearch's proprietary research and validated by in-house industry analysts. These companies represent the key players shaping competition in the Thailand Atherosclerosis Industry, including AstraZeneca, Amgen, and other established names.

List of Atherosclerosis companies in Thailand:

1. AstraZeneca

A leader in cardiovascular medicine, AstraZeneca focuses on transformative science to manage metabolic and renal risks, collaborating with Thai hospitals to enhance heart failure and chronic disease care.

2. Amgen

Specializes in high-science biologics, Amgen provides advanced treatments for cardiovascular risk management and has been instrumental in implementing Fracture Liaison Services in Thai hospitals.

3. Novartis

A pioneer in RNA-based therapy, Novartis delivers innovative small interfering RNA (siRNA) treatments that significantly lower LDL-C levels, addressing the needs of patients with established atherosclerotic disease.

4. Menarini Group

As one of the fastest-growing pharmaceutical companies in Thailand, Menarini provides a diverse portfolio of cardiovascular medications, combining global best practices with localized market insights.

5. Pfizer Inc.

Pfizer remains a foundational player in the Thai market, offering established lipid-lowering therapies and investing in large-scale clinical programs to combat arterial disease progression.

6. Sanofi

Focuses on integrated health solutions, providing a range of cardiovascular treatments and supporting public health awareness campaigns for NCD prevention in Thailand.

7. Abbott Laboratories

Delivers comprehensive diagnostic and therapeutic solutions, supporting the early detection of atherosclerosis through advanced laboratory diagnostics and medical technology.

8. GlaxoSmithKline (GSK)

A global healthcare leader, GSK provides essential medications for cardiovascular health, focusing on long-term disease management and improved patient outcomes in the Thai healthcare ecosystem.

9. Merck & Co., Inc.

Provides robust therapeutic options for cholesterol management and is deeply involved in R&D efforts aimed at reducing the burden of atherosclerosis-related heart disease.

10. Bayer AG

Leverages deep expertise in life sciences to provide effective cardiovascular medicines, focusing on preventive care and the management of chronic conditions associated with arterial plaque.

11. Esperion Therapeutics

An innovative player focused on oral therapies for cholesterol management, providing specialized options for patients who are statin-intolerant or at high risk of cardiovascular events.

Frequently Asked Questions About the Market Study (FAQs):